KMT2A-Rearranged AML: Aligning Care, Guidelines, and Access
Panelists describe the aggressive clinical and molecular features of KMT2A-rearranged acute myeloid leukemia (AML)—including its menin-dependent biology and poor response to standard chemotherapy—while evaluating current and emerging therapies like Menin inhibitors, and highlighting persistent challenges in early diagnosis, equitable access, and delivering specialized care across health care settings.
Episodes
June 13th 2025EP. 1: KMT2A AML Pathogenesis and Presentation
Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to standard therapy, diagnostic challenges, and high relapse risk—underscoring the urgency of RNA-based diagnostics, early transplant consideration, and emerging menin-targeted treatments to improve outcomes.
June 13th 2025EP. 2: Prognosis and Perception of KMT2A AML
Panelists emphasize that patients with KMT2A-rearranged acute myeloid leukemia (AML) often face steep educational challenges at diagnosis, requiring clear communication about the subtype’s adverse-risk classification, biological complexity, and treatment implications—highlighting the need for accessible education, academic-community collaboration, and early referral to specialized care for optimal outcomes.
